![Mark Oki](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Oki
Director of Finance/CFO at
NEOS THERAPEUTICS, INC.
Net worth: 821 375 $ as of 31/07/2026
Profile
Mark K.
Oki is currently Chief Financial Officer at Neos Therapeutics, Inc. and Chief Financial Officer at Achieve Life Sciences, Inc. Formerly, Mr. Oki was Chief Financial Officer, Secretary & Treasurer at Aytu Biopharma, Inc. from 2022 to 2024; Chief Financial & Accounting Officer at VIVUS, Inc. from 2015 to 2019; CFO, Secretary & Senior VP-Finance at Alexza Pharmaceuticals, Inc. in 2015; Controller at Pharmacyclics LLC in 2006; and Assistant Controller at Incyte Corp.
from 1998 to 2001.
Education includes an undergraduate degree from San Jose State University conferred in 1991.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 28/01/2026 | 127,940 ( 0.12% ) | 821 375 $ | 31/07/2026 |
Mark Oki active positions
| Companies | Position | Start |
|---|---|---|
| NEOS THERAPEUTICS, INC. | Director of Finance/CFO | - |
| ACHIEVE LIFE SCIENCES, INC. | Director of Finance/CFO | 05/12/2024 |
Former positions of Mark Oki
| Companies | Position | End |
|---|---|---|
| AYTU BIOPHARMA, INC. | Director of Finance/CFO | 11/11/2024 |
| ALEXZA PHARMACEUTICALS, INC. | Director of Finance/CFO | 16/10/2015 |
| PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | 01/04/2006 |
| INCYTE CORPORATION | Corporate Officer/Principal | 01/01/2001 |
| VIVUS, INC. | Director of Finance/CFO | - |
Training of Mark Oki
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
67
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Manufactures drugs intended to treat cancer and atherosclerosis | Health Technology |
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes next-generation therapies | Health Technology |
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for the acute treatment of central nervous system conditions | Health Technology |
San Jose State University
 San Jose State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets central nervous system-focused products | Health Technology |
Aytu Biopharma, Inc.
 Aytu Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Achieve Life Sciences, Inc.
 Achieve Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes cytisinicline for smoking cessation and nicotine addiction | Health Technology |
- Stock Market
- Insiders
- Mark Oki
